Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: Role of pharmacological modulation

International Heart Journal

Volumn 48, Issue 2, 2007, Pages 233-245

  Sheu, Jiunn Jye ^a   Chang, Li Teh ^b   Chiang, Chiang Hua ^c   Sun, Cheuk Kwan ^a   Chang, Nyuk Kong ^a   Youssef, Ali A ^d   Wu, Chiung Jen ^a   Lee, Fan Yen ^a   Yip, Ho Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d Suez Canal University Hospital   (Egypt)

Author keywords

Apoptosis; Connexin43; Diabetes mellitus; Gap junction; Pharmacological modulation

Indexed keywords

CONNEXIN 43; INSULIN ZINC SUSPENSION; LOSARTAN; PLACEBO; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; GAP JUNCTION; HEART CONTRACTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; IMMUNOFLUORESCENCE TEST; INSULIN TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; CONNEXIN 43; DIABETES MELLITUS, EXPERIMENTAL; GAP JUNCTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; LOSARTAN; MALE; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 34247146297     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.233     Document Type: Article

References (34)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
2. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996; 31:S3-13.
3. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573-9.
4. Laakso MLS. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5:294-315.
5. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In. Harries MI, Cowie CC, Stern MP, et al. eds. Diabetes in America. 2nd ed. Washington DC. Government Printing Office; 1995:233-57.
6. Pyorola K, Laakso M, Unsitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463-524.
7. Barreto-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care 1997; 20:1620-3.
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
9. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetes patients. Circulation 2004; 109: 867-73.
10. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94: 1818-25.
11. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angioplasty predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001; 38: 645-52.
12. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239-42.
13. Poomima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006; 98: 596-605.
14. Jalife J, Morley GE, Vaidya D. Connexins and impulse propagation in the mouse heart. J Cardiovasc Electrophysiol 1999; 10: 1649-63.
15. Vozzi C, Dupont E, Coppen SR, Yeh HI, Severs NJ. Chamber-related differences in connexin expression in human heart. J Mol Cell Cardiol 1999; 31: 991-1003.
16. Severs NJ, Rothery S, Dupont F, et al. Immunocytochemical analysis of connexin expression in the healthy and diseased cardiovascular system. Microsc Res Tech 2001; 52: 301-22,
17. Kirchhoff S, Nelles E, Hagendorff A, Kruger O, Traub O, Willecke K. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol 1998; 8: 299-302.
18. Lemer DL, Yamada, KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000; 101: 547-52.
19. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Cardiac arrhythmogenesis and the gap junction. J Mol Cell Cardiol 1995; 27:37-44.
20. Scarabelli TM, Knight R, Stephanou A, et al. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 2006; 31: 181-264.
21. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Cir Res 2002; 90: 770-6.
22. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
23. Mach F. Statins as immunomodulatory agents. Circulation 2004; 109 (Suppl 1): II15-7.
24. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980; 69: 498-506.
25. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27:528-35.
26. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366-9.
27. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Cir Res 2001; 88: E14-22.
28. Yeh HI, Lai YJ, Lee SH, et al. Heterogeneity of myocardial sleeve morphology and gap junctions in canine superior vena cava. Circulation 2001; 104: 3152-7.
29. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation 2002; 105:2937-8.
30. Kinlay S, Selwyn AP. Effect of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003; 91: 9B-13. (Review)
31. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-31.
32. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: E1-10.
33. Suzuki Y, Ruiz-Ortega, M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900.
34. Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005; 112: 1798-805.